Healthcare >> CEO Interviews >> November 1, 2002

Daniel Korpolinski – Stressgen Biotechnologies Corp (ssb:tse)

DANIEL L. KORPOLINSKI is President and Chief Executive Officer of Stressgen. Mr. Korpolinski has considerable experience in the US public markets and brings to Stressgen a strong track record of successful corporate partnering and managing late stage development companies. He has held a number of senior executive positions within the pharmaceutical industry. From September 1998 to December 1999, Mr. Korpolinski was President and CEO of Copley Pharmaceutical Inc., a generic pharmaceutical company. Mr. Korpolinski managed the sale of Copley Pharmaceutical to Teva Pharmaceutical for the Board and the Shareholders. Between 1991-1996, Mr. Korpolinski served as the President and CEO of CoCensys Inc., a biotechnology company specializing in the development of therapeutics for the central nervous system. During his tenure at CoCensys, he led the company's IPO on NASDAQ and put in place six partnerships with major pharmaceutical companies. From 1988-1991, Mr. Korpolinski was President of Adria Laboratories North America, an oncology company with US sales of over $250 million. Mr. Korpolinski started his career in the pharmaceutical industry with the Upjohn Company spending over 24 years culminating in several corporate positions including Executive Director of one of its Pharmaceutical Business Groups and subsequently its Consumer Products Group. Profile
TWST: Would you begin with an overview of Stressgen


Mr. Korpolinski: The company is over 11 years old; we started in

1990. It had started out as a company looking at heat